MODIFICATION
A -- Cancer Model Development Centers - Amendment 3
- Notice Date
- 6/30/2016
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- 16X042Q
- Archive Date
- 7/20/2016
- Point of Contact
- SBO Help Desk,
- E-Mail Address
-
NCIOASupport@centeva.com
(NCIOASupport@centeva.com)
- Small Business Set-Aside
- N/A
- Description
- S16-042Q Amendment 4 AMENDMENT 3: THIS AMENDMENT PROVIDES THE FOLLOWING ONE (1) CHANGE TO THE SPECIAL NOTICE: (1) THE AMENDED SOLICITATION, AMENDMENT 4, IS ADDED AS AN ATTACHMENT. AMENDMENT 2: THIS AMENDMENT PROVIDES THE FOLLOWING ONE (1) CHANGE TO THE SPECIAL NOTICE: (1) THE AMENDED SOLICITATION, AMENDMENT 3, IS ADDED AS AN ATTACHMENT. AMENDMENT 1: THIS AMENDMENT PROVIDES THE FOLLOWING TWO (2) CHANGES TO THE SPECIAL NOTICE: (1) INFORMATION RELATED TO A BIDDER'S TELECONFERENCE IS ADDED TO THE DESCRIPTION BELOW; (2) THE AMENDED SOLICITATION, AMENDMENT2, IS ADDED AS AN ATTACHMENT. This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of solicitation for offers. In accordance with FAR 15.201(d), this special notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to: 1) publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR); and 2) increase participation by qualified HUBZone small business, small, small disadvantaged, women-owned small business, veteran-owned small business and service-disabled veteran-owned small business concerns, as applicable. This Special Notice contains the Original RFP, RFP Amendment 0001, and the Statement of Objectives (SOO). This special notice will be amended as necessary to maintain the public record of the RFP and any Amendments. The FNLCR is a Government-Owned Contractor-Operated (GOCO) Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research Inc. for the National Cancer Institute (NCI) under Prime Contract No. HHSN261201500003I, which provides Operations and Technical Support (OTS) for the Frederick National Lab. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this notice as no information is being requested. Please be advised that any submissions provided despite the aforementioned notice that no information is requested become Government property and will not be returned, nor will there be any ensuing discussions or debriefings of any responses. Responses submitted to this notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. Background Information : To address the need for better tools to study cancer, this study is being sponsored by the NCI Office of Cancer Genomics (OCG), under the Center for Cancer Genomics (CCG). In collaborations with international institutions, OCG has established a consortium, the Human Cancer Models Initiative (HCMI) whose goal is to make available to the scientific community large numbers of "next generation" in vitro cancer models that are not encumbered with excessive intellectual property constraints. Description of Work : The overall goal of this RFP is to fund 3 to 5 vendors, defined herein as Cancer Model Development Centers (CMDCs). Under this contract, each CMDC will generate 100 fully credentialed cancer models from patient tissues. Cancer models will be developed within one year after a 6 month period in which all IRB and Licensing agreements are completed. Leidos Biomedical Research, Inc. POC: Gina B. McGeehan, Senior Subcontracts Administrator at Gina.McGeehan@nih.gov For information concerning other opportunities with the FNLCR, please refer to: http://ncioa.cancer.gov/oa-internet/sbo/welcome.jsp Bidders Teleconference: A bidders teleconference will be held at 11:00 AM Eastern Time, Monday, June 6, 2016. The telephone number is 855-462-5367; 1848582 Join via: https://cbiit.webex.com/cbiit/j.php?MTID=md8bae9ff26239f7044126ec80523dd16 For help accessing WebEx: contact Gina McGeehan at gina.mcgeehan@nih.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/16X042Q /listing.html)
- Record
- SN04168535-W 20160702/160701000055-d6d7e4fa507d5494317f17cf38350034 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |